Chad E. Mire

TL;DR: It is shown that lipid-nanoparticle-encapsulated short interfering RNAs (siRNAs) rapidly adapted to target the Makona outbreak strain of Ebola virus are able to protect 100% of rhesus monkeys against lethal challenge when treatment was initiated at 3 days after exposure while animals were viraemic and clinically ill.

TL;DR: EBOV VP35 inhibits PACT-induced RIG-I ATPase activity in a dose-dependent manner and impairs the association between VP35 and the viral polymerase, thereby diminishing viral RNA synthesis and modulating EBOV replication.

TL;DR: It is demonstrated that ARB suppresses in vitro infection of mammalian cells with Ebola virus, Tacaribe arenavirus, and human herpesvirus 8 (HHV-8), and proposed as a broad-spectrum antiviral drug that may be useful against hemorrhagic viruses.

TL;DR: Results represent the successful therapeutic in vivo efficacy by an investigational drug against Nipah virus in a nonhuman primate and highlight the potential impact that a monoclonal antibody can have on a highly pathogenic zoonotic human disease.

TL;DR: RVSV filovirus GP vaccine vectors lack the neurovirulence properties associated with the rVSV-wt parent vector and support their further development as a vaccine platform for human use.